These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 17652241)

  • 1. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
    Bertram MY; Lim SS; Wallace AL; Vos T
    Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Australian smokers' use of bupropion and nicotine replacement therapies and their relation to reimbursement, Australia 2001-05.
    Lutsenko H; Doran CM; Hall WD
    Drug Alcohol Rev; 2008 Mar; 27(2):160-4. PubMed ID: 18264876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis.
    Song F; Raftery J; Aveyard P; Hyde C; Barton P; Woolacott N
    Med Decis Making; 2002; 22(5 Suppl):S26-37. PubMed ID: 12369228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
    Annemans L; Nackaerts K; Bartsch P; Prignot J; Marbaix S
    Clin Drug Investig; 2009; 29(10):655-65. PubMed ID: 19715382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.
    Wang D; Connock M; Barton P; Fry-Smith A; Aveyard P; Moore D
    Health Technol Assess; 2008 Feb; 12(2):iii-iv, ix-xi, 1-135. PubMed ID: 18093448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden.
    Bolin K; Lindgren B; Willers S
    Chest; 2006 Mar; 129(3):651-60. PubMed ID: 16537864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
    Hoogendoorn M; Welsing P; Rutten-van Mölken MP
    Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
    Feenstra TL; Hamberg-van Reenen HH; Hoogenveen RT; Rutten-van Mölken MP
    Value Health; 2005; 8(3):178-90. PubMed ID: 15877590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.
    Higashi H; Barendregt JJ
    Addiction; 2012 Mar; 107(3):658-70. PubMed ID: 21883602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison.
    Cornuz J; Gilbert A; Pinget C; McDonald P; Slama K; Salto E; Paccaud F
    Tob Control; 2006 Jun; 15(3):152-9. PubMed ID: 16728744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea.
    Bae JY; Kim CH; Lee EK
    Value Health; 2009; 12 Suppl 3():S70-3. PubMed ID: 20586986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Smoking reduction and temporary abstinence: new approaches for smoking cessation].
    Le Houezec J; Säwe U
    J Mal Vasc; 2003 Dec; 28(5):293-300. PubMed ID: 14978435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Varenicline in the management of smoking cessation: a single technology appraisal.
    Hind D; Tappenden P; Peters J; Kenjegalieva K
    Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of varenicline for smoking cessation.
    Keiding H
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):215-21. PubMed ID: 19527093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
    Howard P; Knight C; Boler A; Baker C
    Pharmacoeconomics; 2008; 26(6):497-511. PubMed ID: 18489200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.
    Vemer P; Rutten-van Mölken MP
    Value Health; 2010; 13(2):230-41. PubMed ID: 19804435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation.
    Taylor M; Leonardi-Bee J; Agboola S; McNeill A; Coleman T
    Addiction; 2011 Oct; 106(10):1819-26. PubMed ID: 21561499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.